NCT04827069View on ClinicalTrials.gov

A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 18, 2018

Primary Completion Date

August 21, 2023

Study Completion Date

August 30, 2023

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Clifutinib Besylate

receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days

Trial Locations (1)

Unknown

the First Affiliated Hospital,College of Medicine,Zhejiang University, Hanzhou

All Listed Sponsors

lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY

NCT04827069 - A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML) | Biotech Hunter | Biotech Hunter